303 related articles for article (PubMed ID: 16885721)
21. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
Mross K; Holländer N; Frost A; Unger C; Ziroli V; Massing U
Onkologie; 2006 Oct; 29(10):444-50. PubMed ID: 17028453
[TBL] [Abstract][Full Text] [Related]
22. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.
Loh GW; Ting LS; Ensom MH
Clin Pharmacokinet; 2007; 46(6):471-94. PubMed ID: 17518507
[TBL] [Abstract][Full Text] [Related]
23. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin.
Zhang JS; Imai T; Otagiri M
Arch Toxicol; 2000 Aug; 74(6):300-7. PubMed ID: 11005675
[TBL] [Abstract][Full Text] [Related]
24. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy.
Dupuis C; Mercier C; Yang C; Monjanel-Mouterde S; Ciccolini J; Fanciullino R; Pourroy B; Deville JL; Duffaud F; Bagarry-Liegey D; Durand A; Iliadis A; Favre R
Anticancer Drugs; 2008 Mar; 19(3):267-73. PubMed ID: 18510172
[TBL] [Abstract][Full Text] [Related]
25. Hepatotoxicity and pharmacokinetics of cisplatin in combination therapy with a traditional Chinese medicine compound of Zengmian Yiliu granules in ICR mice and SKOV-3-bearing nude mice.
Gong C; Qian L; Yang H; Ji LL; Wei H; Zhou WB; Qi C; Wang CH
BMC Complement Altern Med; 2015 Aug; 15():283. PubMed ID: 26283082
[TBL] [Abstract][Full Text] [Related]
26. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.
Loos WJ; Gelderblom H; Sparreboom A; Verweij J; de Jonge MJ
Clin Cancer Res; 2000 Jul; 6(7):2685-9. PubMed ID: 10914710
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration.
Ikeda K; Terashima M; Kawamura H; Takiyama I; Koeda K; Takagane A; Sato N; Ishida K; Iwaya T; Maesawa C; Yoshinari H; Saito K
Jpn J Clin Oncol; 1998 Mar; 28(3):168-75. PubMed ID: 9614438
[TBL] [Abstract][Full Text] [Related]
28. Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin.
Leone R; Fracasso ME; Soresi E; Cimino G; Tedeschi M; Castoldi D; Monzani V; Colombi L; Usari T; Bernareggi A
Cancer Chemother Pharmacol; 1992; 29(5):385-90. PubMed ID: 1312907
[TBL] [Abstract][Full Text] [Related]
29. 5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Vokes EE; Moormeier JA; Ratain MJ; Egorin MJ; Haraf DJ; Mick R; Weichselbaum RR
Cancer Chemother Pharmacol; 1992; 29(3):178-84. PubMed ID: 1733549
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1.
Scott JR; Courter JD; Saldaña SN; Widemann BC; Fisher M; Weiss B; Perentesis J; Vinks AA
Ther Drug Monit; 2013 Jun; 35(3):332-7. PubMed ID: 23666574
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
Vadiei K; Siddik ZH; Khokhar AR; al-Baker S; Sampedro F; Perez-Soler R
Cancer Chemother Pharmacol; 1992; 30(5):365-9. PubMed ID: 1505075
[TBL] [Abstract][Full Text] [Related]
32. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter.
Selting K; Waldrep JC; Reinero C; Branson K; Gustafson D; Kim DY; Henry C; Owen N; Madsen R; Dhand R
J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):255-68. PubMed ID: 18759657
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients.
Urien S; Brain E; Bugat R; Pivot X; Lochon I; Van ML; Vauzelle F; Lokiec F
Cancer Chemother Pharmacol; 2005 Jan; 55(1):55-60. PubMed ID: 15258698
[TBL] [Abstract][Full Text] [Related]
34. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
[TBL] [Abstract][Full Text] [Related]
35. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
Gamelin E; Bouil AL; Boisdron-Celle M; Turcant A; Delva R; Cailleux A; Krikorian A; Brienza S; Cvitkovic E; Robert J; Larra F; Allain P
Clin Cancer Res; 1997 Jun; 3(6):891-9. PubMed ID: 9815764
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin pharmacokinetics and its nephrotoxicity in diabetic rabbits.
Najjar TA; Saad SY
Chemotherapy; 2001; 47(2):128-35. PubMed ID: 11173815
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
[TBL] [Abstract][Full Text] [Related]
38. Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) .
Kim HT; Kim DK; Cho YB; Kim TS; Jung I; Kim KH; Heo DS; Bang YJ; Shin SG; Kim NK
Cancer Chemother Pharmacol; 1998; 41(2):109-16. PubMed ID: 9443623
[TBL] [Abstract][Full Text] [Related]
39. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
Rowinsky EK; Kaufmann SH; Baker SD; Grochow LB; Chen TL; Peereboom D; Bowling MK; Sartorius SE; Ettinger DS; Forastiere AA; Donehower RC
J Clin Oncol; 1996 Dec; 14(12):3074-84. PubMed ID: 8955652
[TBL] [Abstract][Full Text] [Related]
40. Hyperthermic isolated regional perfusion with CDDP for bone and soft-tissue sarcoma of the lower limb: pharmacokinetics, thermal dose, toxicity, and feasibility.
Abe S; Tokizaki T; Miki Y; Tateishi A; Ogawa K; Nakano H; Matsushita T
Cancer Chemother Pharmacol; 2005 Jul; 56(1):55-62. PubMed ID: 15791455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
